Evidence map›Paper›PMID 37596578›Full record

ArticleBMC cancer2023

Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC: the RALLY protocol.

Daan Andel, Marnix G E H Lam, Joep de Bruijne, Maarten L J Smits, Arthur J A T Braat, Adriaan Moelker, Erik Vegt, Simeon J S Ruiter, Walter Noordzij, Gianluca Grazi and 10 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Daan AndelDepartment of Surgical Oncology, University Medical Center Utrecht, Cancer Center, PO BOX 85500, 3508 GA, Utrecht, The Netherlands. D.S.H.Andel-3@umcutrecht.nl.ORCID http://orcid.org/0000-0001-9858-868X
Marnix G E H LamDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
Joep de BruijneDepartment Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, the Netherlands.
Maarten L J SmitsDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
Arthur J A T BraatDepartment of Radiology and Nuclear Medicine, University Medical Center Utrecht, Cancer Center, Utrecht, The Netherlands.
Adriaan MoelkerDepartment of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Erik VegtDepartment of Radiology and Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Simeon J S RuiterDepartment of HPB & Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.
Walter NoordzijDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands.
Gianluca GraziHepatopancreatobiliary Surgery, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Giulio E VallatiInterventional Radiology, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Roel J BenninkDepartment of Radiology and Nuclear Medicine, Cancer Center, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
Otto M van DeldenDepartment of Radiology and Nuclear Medicine, Cancer Center, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
Onno W KranenburgDepartment of Surgical Oncology, University Medical Center Utrecht, Cancer Center, PO BOX 85500, 3508 GA, Utrecht, The Netherlands.
Jan N M IjzermansDepartment of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Maarten W NijkampDepartment of HPB & Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.
Joris I ErdmannDepartment of Surgery, Cancer Center, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Rosa SciutoNuclear Medicine, IRCCS - Regina Elena National Cancer Institute, Rome, Italy.
Jeroen HagendoornDepartment of Surgical Oncology, University Medical Center Utrecht, Cancer Center, PO BOX 85500, 3508 GA, Utrecht, The Netherlands.
Inne H M Borel RinkesDepartment of Surgical Oncology, University Medical Center Utrecht, Cancer Center, PO BOX 85500, 3508 GA, Utrecht, The Netherlands. I.H.M.BorelRinkes@umcutrecht.nl.
University Medical Center Utrecht · NLAmsterdam University Medical Centers · NLErasmus MC · NLIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity Medical Center Groningen · NLUtrecht University · NL

Funding

Terumo Terumo IO-057-QS
6 · The paper itself

Abstract

backgroundHigh dose unilobar radioembolization (also termed 'radiation lobectomy')-the transarterial unilobar infusion of radioactive microspheres as a means of controlling tumour growth while concomitantly inducing future liver remnant hypertrophy-has recently gained interest as induction strategy for surgical resection. Prospective studies on the safety and efficacy of the unilobar radioembolization-surgery treatment algorithm are lacking. The RALLY study aims to assess the safety and toxicity profile of holmium-166 unilobar radioembolization in patients with hepatocellular carcinoma ineligible for surgery due to insufficiency of the future liver remnant.

methodsThe RALLY study is a multicenter, interventional, non-randomized, open-label, non-comparative safety study. Patients with hepatocellular carcinoma who are considered ineligible for surgery due to insufficiency of the future liver remnant (< 2.7%/min/m DISCUSSION: This will be the first clinical study to assess the unilobar radioembolization-surgery treatment algorithm and may serve as a stepping stone towards its implementation in routine clinical practice.

trial registrationNetherlands Trial Register NL8902 , registered on 2020-09-15.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsClinical Trials as TopicHepatomegalyHolmiumHumansMicrospheresMulticenter Studies as TopicProspective StudiesQuality of LifeRadioisotopesHolmiumHolmium-166Radioisotopes166HoHepatocellular carcinomaHolmium-166Radiation lobectomyRadioembolizationUnilobar radioembolization

Identifiers

PMID37596578
PMCPMC10436405
OpenAlexW4385985983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.